Discontinued — last reported Q1 '24
West Pharmaceutical Services Smart Dose — Deferred income, noncurrent decreased by 23.1% to $1.00M in Q1 2024 compared to the prior quarter. Year-over-year, this metric declined by 47.4%, from $1.90M to $1.00M. Over 2 years (FY 2021 to FY 2023), Smart Dose — Deferred income, noncurrent shows a downward trend with a -30.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates a strong multi-year backlog and long-term commitment from pharmaceutical partners, while a decrease may suggest the maturation of long-term contracts.
Represents the portion of deferred income related to the Smart Dose platform that is expected to be recognized as revenu...
Similar to long-term deferred revenue or non-current contract liabilities seen in companies with multi-year R&D or licensing contracts.
wst_segment_smart_dose_deferred_income_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.40M | $3.20M | $3.00M | $2.80M | $2.50M | $2.30M | $2.10M | $1.90M | $1.70M | $1.50M | $1.30M | $1.00M |
| QoQ Change | — | -5.9% | -6.3% | -6.7% | -10.7% | -8.0% | -8.7% | -9.5% | -10.5% | -11.8% | -13.3% | -23.1% |
| YoY Change | — | — | — | — | -26.5% | -28.1% | -30.0% | -32.1% | -32.0% | -34.8% | -38.1% | -47.4% |